Healthcare Industry News: C.R. Bard
News Release - August 17, 2009
Insulet Appoints Peter J. Devlin as Chief Commercial OfficerBEDFORD, Mass., Aug. 17 (Healthcare Sales & Marketing Network) --Insulet Corporation (Nasdaq: PODD ), the leader in tubing-free insulin pump technology with its OmniPodŽ Insulin Management System, today announced the appointment of Peter J. Devlin as Chief Commercial Officer. In this newly created role, Mr. Devlin will lead the Company's Sales and Marketing, Business Development, Clinical Research and Customer Care operations.
"Peter brings a distinguished track record in the diabetes and medical device industries and we are extremely pleased to have him join Insulet's management team," said Duane DeSisto, president & chief executive officer of Insulet. "Peter's proven ability to develop and implement successful commercial strategies globally will be invaluable to Insulet as we continue to grow our core insulin pump business and expand into new opportunities for the easy-to-use OmniPod System."
Mr. Devlin spent the last 11 years at Abbott Laboratories, most recently serving as Divisional Vice President of Global Strategic Marketing, Diabetes Care. In this role, he was responsible for the development of commercial strategies, global brand management, market research, area strategic marketing, and business analytics and forecasting. Previously, Mr. Devlin served as Marketing Manager of i-STAT Corporation, a point-of-care blood analysis systems company, which was acquired by Abbott. Prior, Mr. Devlin spent eight years at C.R. Bard Inc., where he held various product management and engineering roles of increasing responsibility. Mr. Devlin holds a Bachelor of Science degree in Mechanical Engineering from the University of Massachusetts.
"I am eager to join Insulet at this exciting time as the OmniPod System transitions from being a new technology to the standard of care in the insulin pump market," said Mr. Devlin. "I am also excited to help Insulet realize the promise of its innovative delivery system in a broad range of therapies."
About Insulet Corporation
Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.